“Pathaway speak our language. Their network and expertise within the UK’s IVD (in vitro diagnostic) market is outstanding”, on June 5 ISAB CEO Lena Heffler met with representatives…
“Pathaway speak our language. Their network and expertise within the UK’s IVD (in vitro diagnostic) market is outstanding”, on June 5 ISAB CEO Lena Heffler met with representatives…
(Stockholm, 28 May, 2019) ISAB is making a major investment in validating its flagship aerosol R&D system for clinical use. Why is it such a vital step strategically?…
Stockholm is a world-famous hotspot for game-changing, early-stage life science companies—but which really have the most commercial potential? Funded by the EU European Regional Development Fund, the Invest…
DissolvIt is in demand: Inhalation Sciences (ISAB) has received a new Contract Research order worth EURO 20,000. The client has chosen again to go with DissolvIt, ISAB’s lung…
Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine) is one of the world’s leading toxicology research organizations. At the SOT (Society of Toxicology) 2019 Conference in Baltimore it…
Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine) is one of the world’s leading toxicology research organizations. At the SOT (Society of Toxicology) 2019 Conference in Baltimore it…
From cystic fibrosis to antibiotics, work on new inhalable biologic therapies is growing. With biologics formulated as liquid solutions, the need for precisely controllable wet, as well as…
Fraunhofer ITEM’s regular ‘Models of Lung Disease’ seminars are an influential meeting place for industry and academia to share knowledge on predictive lung disease models and translational lung…
Use of PBPK modelling to evaluate the performance of DissolvIt ®, a biorelevant dissolution assay for orally inhaled drug products. Mireille Hassoun, Maria Malmlof, Otto Scheibelhofer, Abhinav Kumar, Sukhi Bansal, Ewa Selg, Mattias Nowenwik, Per Gerde, Snezana…
